Brief: Can Fite Biopharma Says Completed Pre-Clinical Studies Demonstrating Cbd Rich T3/C15 Cannabis Fraction Induces Inhibition Of Liver Cancer Cell Growth
05/04/2021 12:12
April 5 (Reuters) - Can Fite Biopharma Ltd CANF.TA :
* CAN FITE BIOPHARMA - COMPLETED PRE-CLINICAL STUDIES
DEMONSTRATING CBD RICH T3/C15 CANNABIS FRACTION INDUCES
INHIBITION OF LIVER CANCER CELL GROWTH
Source text for Eikon: ID:nBw3zwqMMa
Further company coverage: CANF.TA
((reuters.briefs@thomsonreuters.com;))
Recent news on Can Fite Biopharma
See all newsBrief: Corrected-Can Fite Biopharma Ltd Files For Offering Of Up To 6.6 mln Ordinary Shares By Selling Shareholders
Can-Fite BioPharma rises after longer-than-anticipated overall survival in ongoing liver cancer study
Can-Fite BioPharma reports longer-than-anticipated overall survival in ongoing liver cancer study
Brief: Can Fite Biopharma Can-Fite Submits Phase 2 Study Protocol For Piclidenoson In Lowe Syndrome
Can-Fite rises as skin drug study reaches interim analysis stage